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Role of Subcellular ROS in 
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Endothelium
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Abstract
For decades, elevated levels of reactive oxygen species (ROS) have been associ-
ated with the pathogenesis of cardiovascular diseases (CVD), including myocardial 
ischemia and infarction (MI). However, several large clinical trials failed to dem-
onstrate beneficial outcomes in response to the global reduction of ROS in patients 
with underlying CVD. Recent studies from our and other labs showed that it is 
rather a critical balance between mitochondrial and cytosolic ROS than total ROS 
levels which determines resilience of coronary endothelial cells (EC). Here, we will 
discuss published and unpublished work that has helped elucidate the molecular 
mechanisms by which subcellular ROS levels, duration and localization modulate 
metabolic pathways, including glycolysis and oxidative phosphorylation, energy 
production and utilization, and dNTP synthesis in EC. These redox-regulated 
processes play critical roles in providing resilience to EC which in turn help protect 
existing coronary vessels and induce coronary angiogenesis to improve post-MI 
recovery of cardiac function.
Keywords: endothelial cell metabolism, angiogenesis, vascular endothelial growth 
factor (VEGF), nitric oxide, reactive oxygen species (ROS), glycolysis, dNTP,  
fatty acid oxidation
1. Introduction
A single layer of endothelial cells (ECs) that covers the vascular lumen and 
plexus exhibits great plasticity to adapt to environmental cues [1, 2]. It is fascinating 
how the vascular system, the largest organ system of the body, connects all organs to 
secure adequate nutrients and blood supply. For that reason, maintaining vascular 
homeostasis is crucial for the health of the cardiovascular system. In a healthy body, 
although the ECs are an intricate, dynamic system, they appear to be in a quiescent 
state [1]. In pathological conditions such as ischemia and infarction, ECs rapidly 
switch phenotype to form new vessels in a process known as sprouting angiogenesis 
[3]. Reactive oxygen species (ROS) are believed to play crucial roles in determining 
the phenotype and fate of EC in both physiological and pathological conditions. 
Recent work has shown that a critical balance between mitochondrial and cytosolic 
ROS levels, but not global ROS levels, modulates endothelial function, EC metabo-
lism and angiogenesis, and thus determines resilience of coronary EC [4–8]. In 
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this chapter, we will discuss the molecular mechanisms by which subcellular ROS 
modulate various metabolic pathways, regulate EC function and angiogenesis.
2. Reactive oxygen species in coronary endothelium
Previously, the pathology of cardiovascular diseases (CVD), including myo-
cardial ischemia and infarction (MI), was believed to be associated with increased 
levels of ROS [4–8]. Recent studies show that it is rather a critical balance between 
cytosolic and mitochondrial ROS levels than total ROS levels which determine the 
resilience of coronary ECs in physiological as well as adverse conditions [6, 7, 9, 10].
ROS are produced in higher levels as a response to injuries by the cellular 
enzymes and mitochondria [8, 11]. ROS have been reported to contribute to the 
underlying pathology in almost all organs, and thus the notion that antioxidants 
would ameliorate pathological effects of ROS came into being. However, clinical 
trials failed to show beneficial effects of antioxidants in the treatment of CVD [12]. 
Other studies showed that decreased ROS levels had rather deleterious effects on 
CVD [6, 7]. Also, decreased ROS levels resulted in the inactivation of endothelial 
nitric oxide synthase (eNOS) and reduction in NO (nitric oxide) levels [11, 13]. 
Taken together, global reduction of ROS appeared to reduce endothelial resilience. 
It is crucial to note that ROS have paradoxical effects on ECs, and thus careful study 
of the levels, durations and sources of ROS while studying effects of ROS on EC will 
help advance our understanding of EC resilience during oxidative stress.
2.1 Source of reactive oxygen species in ECs
ROS are produced from different oxidoreductase enzymes and locations includ-
ing NADPH oxidase, mitochondrial, xanthine oxidase, cytochrome P450 monooxy-
genase, and uncoupling of NOS [8, 11, 14]. In the vasculature, ECs rely on glycolytic 
pathways as their source of energy, thus NADPH oxidase enzymes appear to be 
the major source of ROS in both physiological and pathological conditions [14]. 
NADPH enzymes have different isoforms, and the major contributors are NOX1, 
NOX2, NOX4, and NOX5 [15, 16]. Recent studies showed importance of NOX2- and 
NOX4-derived ROS in endothelial survival or dysfunction, depending on their 
subcellular location and duration [8].
2.2 Endothelial NADPH oxidase as a major source of ROS in ECs
NADPH oxidase is an intracellular complex enzyme containing membrane-
bound and cytosolic regulator subunits [14, 17, 18]. This enzyme produces ROS by 
transferring electrons from NAD(P)H to an oxygen molecule and is considered 
the major source of ROS in coronary endothelium. Distinct isoforms of NADPH 
enzymes have been shown to exhibit different physiological and pathological 
responses in vascular homeostasis.
NOX1 enzyme is primarily expressed in the vascular smooth muscle cells 
(VSMC) and it contributes to VSMC proliferation and migration [11, 19–21]. 
In disease conditions, NOX1 contributes to the impairment of endothelium-
dependent vasorelaxation, as well as the augmentation of angiotensin II vasomotor 
response [11, 22, 23]. A study showed that NOX1-deficient mice attenuated the 
levels of ROS, neointimal growth, and migration. These findings suggest that the 
downregulation of NOX1 enzyme can prevent the formation of atherosclerotic 
plaque [15, 24]. Yet, further studies are warranted to explore the exact role of 
NOX1 in endothelial signaling.
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In contrast, NOX2 enzyme has exhibited positive effects on coronary ECs. NOX2 
enzyme stimulates the production of NO by the activation of AMPK-eNOS axis 
through Ca2+−/calmodulin-dependent protein kinase kinase β (CaMKKβ) [6] result-
ing in coronary vasodilation, EC proliferation and migration. Although several 
studies support the beneficial effects of NOX2, they also exert detrimental effects 
on coronary EC depending on the duration of exposure. Short exposure of elevated 
ROS levels was associated with the previously mentioned pathway (i.e. CaMKKβ 
pathway). On the contrary, prolonged exposure of high ROS levels resulted in 
decrease bioavailability of NO, inactivation of mitochondrial antioxidant MnSOD 
[7, 8], and decreased EC proliferation and coronary vasodilatation.
NOX4 enzyme is abundant in human ECs [8] and produces H2O2 molecules 
rather than O2
− [9, 11, 25–28]. NOX4 enzyme stimulates vascular angiogenesis 
through the activation of transforming growth factor β1 (TGF β1), and increases 
hemoglobin content [29]. NOX4-derived ROS cause vasodilation through endothe-
lium hyperpolarization [30–32]. This occurs via the stimulation of endothelium 
Ca2+-activated K+ channel that causes the release of Ca2+ from the endoplasmic 
reticulum [29]. Additionally, NOX4 enzyme activates heme oxygenase-1 (HO-1), 
which confers a vascular protective response via different mechanisms [29]. Thus, 
therapeutic modalities that advocate for antioxidants in CVD needs careful consid-
eration of the source and location of ROS.
Calcium-dependent NADPH oxidase, NOX5, is implicated in angiogenic 
response [33, 34]. It gets its name from its structure because it has an additional 
N-terminal region that binds to calcium [33]. This unique structure allows the 
enzyme activation through increased intracellular calcium. Similar to NOX4, NOX5 
enzyme seems to produce predominantly H2O2 in ECs [24]. H2O2 has been impli-
cated in the development of atherosclerotic plaque plausibly by increasing Ca2+ 
levels to promote eNOS-mediated NO synthesis and increasing nitroxide radicals 
[24]. One mechanism may include increased consumption of NO by ROS. Thus, it 
has been hypothesized that inhibition of NOX5 enzyme may show beneficial results 
by precluding oxidant injury to vascular EC.
NADPH enzyme isoforms have distinct locations and EC phenotypes. They have 
been shown to employ different physiological and pathological responses in vascular 
homeostasis. As discussed above, NOX1, NOX2, NOX4, and NOX5 are found in the 
vascular system and they contribute to endothelial resilience through several mecha-
nisms. The roles of NADPH enzymes in physiological and pathological conditions have 
undergone a considerable evolution in recent years. However, further studies are nec-
essary to deepen our understanding of their roles and contributions to EC resilience.
2.3 Endothelial mitochondrial ROS
Although oxidative phosphorylation in mitochondria play a major role in synthe-
sizing energy in most tissues, EC primarily depends on anaerobic glycolysis for 85% 
of its ATP generation. ECs have fewer mitochondria and consume lower amounts 
of O2 than other cell types, and thus mitochondrial ROS are believed to be a minor 
source of ROS in EC in physiological conditions. However, recent studies demon-
strated that sustained increase in NADPH oxidase-derived cytosolic ROS may affect 
the levels of mitochondrial ROS and thus mitochondrial function in EC [6–8].
3. Metabolic pathways in ECs
EC metabolism plays an important role in facilitating cellular proliferation and 
migration during the process of angiogenesis. Alterations in metabolic pathways 
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are necessary to provide energy supplies in the most efficient way under certain 
circumstances that induces blood vessel sprouting such as hypoxia. In addition, 
these alterations mediate the formation of important molecules that are essential for 
cytoskeletal remodeling during the process. This section highlights some of these 
metabolic pathways and their role in angiogenesis.
3.1 Glycolysis
Glycolysis is a major metabolic pathway that is utilized for energy production 
through the anaerobic oxidation of glucose molecules [35, 36]. It is the major source 
of ATP in ECs. Glycolysis involves consumption of 2 ATP molecules, and the end 
products include 4 ATP, 2 NADH and 2 pyruvate molecules (Figures 1 and 2). 
Subsequently, pyruvate can be shifted to the mitochondria and metabolized into 
acetyl-CoA to be used in the tricarboxylic acid cycle (TCA). The substrates and 
products of this process are as follows:
 
+ +
+ + + ® + + + +Glucose NAD ADP Pi Pyruvate NADH H ATP H O.
2
2 2 2 2 2 2 2 2
Glycolysis occurs in the cytosol, and the process does not require oxygen 
(anaerobic), therefore it constitutes the primary source of energy in cells that lack 
mitochondria (e.g. red blood cells). In addition, glycolysis is the main source of 
pyruvate, which is converted to acetyl-CoA to be utilized in the TCA cycle in cells 
Figure 1. 
The investment phase of glycolysis and regulation of the rate limiting PFK1 enzyme by fructose-2, 
6-bisphosphate and AMP.
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that use oxidative phosphorylation (aerobic respiration) as a primary source of 
ATP. Also, glycolysis is a more efficient source of energy in periods of hypoxia and 
ischemia when oxygen supply becomes scarce.
3.1.1 Mechanisms of glycolysis
The first step in glycolysis constitutes the investment phase of glycolysis, in 
which 2 ATP molecules are consumed as shown in Figure 1. It involves trapping of 
the glucose molecule inside the cell via phosphorylation into glucose-6-phosphate 
[35, 36]. This reaction is catalyzed by glucokinase in the liver and pancreatic β cells, 
or a hexokinase enzyme in the rest of body cells. It also involves the transfer of a 
phosphate group from an ATP molecule. Next, glucose-6-phosphate is converted 
to fructose-6-phosphate by an isomerase. This is followed by the rate-limiting step 
of glycolysis, which involves the phosphorylation of fructose-6-phosphate into 
fructose-1-6-bisphosphate by phosphofructokinase 1 (PFK1). This step is critical in 
the glycolytic pathway and the PFK1 enzyme is highly regulated by multiple factors 
that determine the direction of the reaction. Fructose-1-6-bisphosphate is subse-
quently converted by an aldolase into dihydroxyacetone phosphate (DHAP) and 
glyceraldehyde-3-phosphate (G3P).
The following reactions constitute what can be referred to as the payoff phase of 
glycolysis. It is also important to remember that at this stage, we have two 3-car-
bon molecules per 1 glucose molecule as shown in Figure 2. G3P is converted to 
1-3-diphosphoglycerate, generating NADH in the process. 1-3-diphosphoglycerate 
then loses a phosphate group to 3-phosphoglycerate via phosphoglycerate kinase, 
which generates an ATP molecule. 3-phosphoglycerate is subsequently converted 
Figure 2. 
The payoff phase of glycolysis.
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in a two-step reaction into phosphoenolpyruvate (PEP). Finally, pyruvate kinase 
converts PEP into pyruvate, generating ATP in the process. Thus, the end product 
of glycolysis includes 4 ATP molecules, but because of the initial consumption of 2 
ATP, the return on investment includes 2 ATP molecules per glucose [35, 36].
3.1.2 Regulation of glycolysis
The availability of glucose regulates the rate of glycolysis and is determined by 
two main mechanisms: glucose uptake from the blood, and breakdown of glycogen 
[35, 37]. In addition, the amount of oxygen can also regulate glycolysis through 
what is called the “Pasteur Effect”, which describes how increased oxygen levels 
inhibit glycolysis, and decreased availability results in acceleration of glycolysis 
[35]. Within the glycolytic pathway, PFK1, which catalyzes the rate limiting step is 
considered the main player in terms of glycolysis regulation, and its activity can be 
affected in a number of ways.
Fructose 2–6 bisphosphate is an allosteric regulator of PFK1, which increases 
the enzyme activity [35, 37]. It is produced by phosphofructokinase 2 (PFK2), 
an enzyme that has both kinase and phosphorylase activity and can transform 
fructose 6 phosphates to fructose 2,6 bisphosphate and vice versa. Insulin dephos-
phorylates PFK2 activating its kinase activity, and increasing fructose 2,6 bispho-
sphate production, which subsequently activates PFK1 (Figure 1). Moreover, 
Glucagon phosphorylates PFK2, activating its phosphatase, which transforms 
fructose 2,6 bisphosphate back to fructose 6 phosphate. This decreases fructose 
2,6 bisphosphate levels and decreases PFK1 activity. Low energy levels within 
the cell which result in increased AMP and low ATP/AMP ratio, induce allosteric 
activation of PFK1.
3.1.3 Glycolysis and EC angiogenesis
The endothelium is one of the most diverse tissues in the human body, which 
displays significant organ-specific heterogeneity. This diversity determines the 
function of the endothelium according to the organ being supplied [38]. Since ECs 
lining blood vessels are responsible for supplying oxygen and nutrient to body tis-
sues, the ability to expand this network of blood vessels via angiogenesis is critical 
for organ growth and function in health and disease [39]. Low oxygen levels serve 
as a primary stimulus for angiogenesis, which in its classic meaning refers to the 
sprouting of branches from the existing vessels.
3.1.3.1 Angiogenesis
ECs are essential for the normal functioning of the vascular system. They drive 
the vascular system expansion during physiologic organ growth to supply suf-
ficient nutrients, as well as under pathologic conditions through a process known 
as angiogenesis (Figure 3). Angiogenesis depends highly on the coordinated 
orchestra of several regulatory steps [1]. Briefly, this process is guided by the 
migratory non-proliferative “tip” cells at the forefront from an existing vessel, 
while the “stalk” cells trail the proliferative and elongation part of the sprout. 
“Tip” and “stalk” cells continuously switch their phenotype between being either 
tip or stalk cells. For example, the “tip” cell becomes a “stalk” cell when it loses its 
migratory behavior, and the “stalk” cell will compete for the position [1]. Several 
studies found that the vascular endothelial growth factor (VEGF) controls the 
“tip” cells induction, filopodia formation, and expression of the Notch ligand 
Delta–like 4 (NLD4) [40, 41]. NLD4, subsequently, suppresses VEGF receptor 2 
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(VEGFR2/kdr/Flk1) and thus modulates the tip cell behavior. While many genetic 
and molecular signaling pathways were recognized to be part of this process, the 
role of ECs metabolism has not been studied and explored until recently.
Switching on the angiogenic machinery of ECs has significant consequences on 
EC metabolism. This is because angiogenic ECs require nutrients and energy not 
only for motility but also for the synthesis of building blocks (proteins, nucleotides, 
and lipids) for cellular proliferation. Hence, during angiogenesis, ECs must increase 
their metabolic activity to generate energy quickly, while at the same time meeting 
the challenge of scarce resources as they proliferate in harsh hypoxic environments. 
Therefore, EC metabolism has to be flexible to support vessel formation under 
different conditions [39, 42].
Upon switching from quiescence state to vessel branching, the rate of gly-
colysis is increased in order to fuel subcellular processes required for migration 
such as cytoskeleton remodeling. Notably, the pro-angiogenic VEGF increases 
expression of the glycolysis activator phosphofructokinase-2/fructose-
2,6-bisphosphatase 3 (PFKFB3) [43]. PFKFB3 generates higher levels of fructose-
2,6-bisphosphate, which activates phosphofructokinase 1, the rate limiting 
enzyme in glycolysis [43, 44]. In fact, studies have shown that genetic and 
pharmacologic inhibition of the phosphofructokinase 2 reduced EC sprouting 
and branching capacity [44, 45]. Another regulator enzyme is the hexokinase-2 
(HK2) which phosphorylate glucose to glucose-6-phosphate [44, 46]. Several 
transcription factors such as KLF2 and forkhead box 1 (FOXO1) were found to 
suppress these key glycolytic enzymes in the quiescent phalanx cells [47, 48]. 
However, the rate of glycolysis increases in the actively sprouting tip and stalk 
cells due to VEGF-mediated activation of PFKFB3 and the decreased levels of 
KLF2 and FOXO1. Interestingly, PFKFB3 and other glycolytic enzymes are highly 
concentrated in filopodia to generate ATP at the so-called ‘ATP hot-spots’. And 
several studies showed that pharmacologic or genetic inhibition PFKFB3 impairs 
new vessel formation [43, 44].
Figure 3. 
Angiogenesis is mainly regulated via VEGF. Tip cells require increasing amounts of ATP necessary for migration 
into hypoxic tissues while proliferating stalk cells generate building blocks (dNTP, protein) to maintain their 
growth and cellular division.
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3.1.3.2 Endothelial cell metabolism
Despite the fact that oxygen is readily available for EC consumption, the glyco-
lytic pathway remains primary source of energy for EC [38, 44, 49]. In fact, 85% 
of EC energy production in the form of ATP is generated through glycolysis, even 
though oxidative phosphorylation (OXPHOS) can generate significantly larger 
amounts of ATP molecules at much faster rate [43, 49, 50]. However, ECs have fewer 
mitochondria and consume lower amounts of O2 than other cell types, especially in 
the presence of abundant supplies of glucose, where only a small fraction of pyru-
vate is shifted to the TCA cycle [39, 43, 50]. Nonetheless, ECs retain their capacity 
for oxidative metabolism when glycolysis is compromised or in conditions of stress. 
Surprisingly, even though the amount of energy generated per glucose molecule 
via oxidative phosphorylation is significantly greater, higher rates of glycolysis can 
provide more ATP in a shorter period of time when glucose supply is unlimited. In 
fact, the rate of glycolysis is high in EC compared to other normal cells, and their 
glucose consumption is comparable with that of some cancer cells [43].
A logical question that can be asked here is, why do ECs depend on glycolysis for 
their energy production when they have direct supply of oxygen from blood? There 
are several explanations for this observation. First, despite the fact that the energy 
yield via glycolysis is significantly low compared to aerobic respiration, glycolysis can 
generate ATP molecules at a much faster rate [39, 49]. This is especially important 
when considering the energy requirements of ECs during angiogenesis. In addition, 
anaerobic glycolysis facilitates ECs sprouting and proliferation in hypoxic tissues 
and makes them resistant to hypoxic insults [39]. Also, it limits ROS generation and 
produces larger amounts of lactic acid, which acts as a pro-angiogenic factor [38, 39, 
44]. Moreover, oxygen can be spared to be utilized by the underlying tissue cells. The 
low oxygen dependence allows sprouting cells to explore and reach distant hypoxic 
tissues [44]. Also, low oxygen consumption by ECs facilitates oxygen delivery to 
vital organs. Furthermore, glycolysis provides essential metabolites that are used in 
multiple cellular pathways such as pentose phosphate pathway (PPP), hexosamine 
biosynthesis pathway (HBP) and 3-phosphoglycerate (G3P) which generate impor-
tant molecules and compounds that are used in different cellular processes [39, 49]. 
Thus, glycolysis provides a metabolic platform that allows ECs to perform diverse 
roles in the growing and resting vasculature with minimal ROS generation.
3.1.3.3 Alternative metabolism of glucose
ECs engage in several other pathways that can potentially affect angiogenesis, 
but their exact roles are understudied. Once phosphorylated by hexokinase (HK), 
glucose-6-phosphate (G6P) can be used to form glycogen, which could serve as an 
endogenous source of glucose when ECs sprout into glucose-deprived milieu. In fact, 
inhibition of glycogen phosphorylase (PYG), was found to impair EC migration [51].
G6P can also enter the pentose phosphate pathway (PPP) to generate NADPH 
[44]. NADPH is essential for restoring the reduced form of glutathione (GSH) from 
its oxidized form (GSSG), which serves as an antioxidant [38, 52]. PPP provides two 
intermediates of glycolysis, fructose-6-phosphate (F6P) and glyceraldehyde-3-phos-
phate (G3P). Interestingly, inhibition of G6P dehydrogenase (G6PD) or Transketolase 
(TKT) in the PPP was found to impair EC viability and migration [44].
3.1.3.4 Pathways regulation
ECs react to environmental conditions and energy requirements through several 
mechanisms that involve cellular molecules sensing changes in energy levels. One 
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of these molecules is the AMP-kinase (AMPK), which gets activated by the rising 
levels of AMP as energy levels dwindle. Activation of AMPK-mediated phosphory-
lation of metabolic targets promotes catabolic pathways and ATP production, 
while inhibiting anabolic pathways that consume ATP [39, 53]. This allows ECs to 
balance their energy level according to environmental changes. For instance, AMPK 
increases energy production via fatty acid oxidation (FAO) in EC mitochondria and 
help maintain ATP levels when glucose supplies are low [39, 54]. In addition, AMPK 
is activated by EC-specific stimuli such as hypoxia and shear stress generated by 
blood flow [38]. Interestingly, inhibition of AMPK was found to hinder EC angio-
genesis in response to hypoxia [55].
3.2 Oxidative phosphorylation
The mechanism by which ATP is produced in the mitochondria via oxidative 
phosphorylation (OxPhos) was first discovered in the second half of the twen-
tieth century [56, 57]. OxPhos is a process that involves the use of high-energy 
intermediates for energy transduction between the electron transport chain of the 
mitochondria and the chemical synthesis of ATP from ADP and phosphate. OxPhos 
generates 15 times the amount of ATP produced by glycolysis during anaerobic con-
ditions. The reaction involves oxygen consumption, and energy is released from the 
high energy molecules (NADH, FADH2) and stored in the form of an electrochemi-
cal proton gradient across the inner mitochondrial membrane. This energy extrac-
tion occurs in three steps each catalyzed by a specific membrane complex including 
Complex I (NADH dehydrogenase), Complex III (Cytochrome bc1) and Complex 
IV (Cytochrome oxidase/COX). Complex II (Succinate dehydrogenase) converts 
succinate to fumarate, a TCA cycle intermediate, and in the process H+ is produced 
from FADH2, which is then shunted by Complex III across the inner mitochondrial 
membrane. COX is also considered the rate-limiting step of this aerobic respiration. 
Eventually, the electrochemical proton gradient is utilized by Complex V (ATP 
Synthase) to produce ATP, or it can be dissipated in the form of heat by passive 
proton leakage [56, 58, 59].
The electron transport chain is regulated through different mechanisms. 
Allosteric effectors such as ADP and ATP regulate the process by binding to their 
specific binding sites on the different mitochondrial complexes. Regulation of the 
enzyme activity by ATP or ADP binding to the same site on the complex subunit 
depends on the ATP/ADP ratio. For instance, the exchange of bound ADP by ATP 
on COX results in an allosteric ATP synthesis inhibition at an ATP/ADP ratio of 28 
[60]. In addition, phosphorylation and dephosphorylation of the enzyme com-
plexes is considered another mean of regulating the electron transport chain. For 
example, phosphorylation of COX was found to inhibit the enzyme activity [56].
3.3 Fatty acid oxidation contribute to dNTP synthesis
Deoxyribonucleoside Triphosphate (dNTP) is a molecule consisting of a deoxy-
ribose sugar attached to three phosphate groups and one of the nucleotide bases, 
adenine, guanine, cytosine, or thymine as shown in Figure 4 [61]. Apart from DNA 
replication, dNTPs may also function as a source of energy for different cellular 
reactions and signaling pathways [62].
3.3.1 dNTP formation
There are two biosynthetic pathways for nucleotides formation: de novo and 
salvage [62]. The de novo pathways require high energy and the use of raw material 
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like glucose, glutamine, aspartate, and HCO3 to form nucleotides [62, 63]. However, 
salvage pathways exist as an alternative energy-efficient route to form nucleotides [63].
The enzyme ribonucleotide reductase (RR), which is NADPH-dependent, 
is responsible for catalyzing the rate-limiting reaction in which ribonucleotides 
are converted to their respective deoxyribonucleotides [62, 63]. This reaction is 
regulated by the number of RR enzymes and allosteric control mechanism [62, 63]. 
RR consists of two nonidentical subunits, α and β. α subunit has the catalytic site, 
substrate-specificity site, and activity site; whereas the β subunit contains a stable 
tyrosyl free radical [63]. The activity of RR enzymes is tightly controlled by allosteric 
mechanism [63, 64]. The reduction of ribonucleotides requires a specific positive 
effector, however, the product dNTP can also serve as a negative effector on the 
enzyme (Table 1) [61, 63].
dNTPs levels and RR enzyme activity are important to control the fidelity of 
nuclear and mitochondrial DNA replication and repair. It has been reported that 
increased levels of dNTP, in vitro, decreased the length of ‘S phase’ of the cell 
cycle during DNA replication, which implies that under physiological conditions, 
nucleotides are used mainly for DNA synthesis [65, 66]. Interestingly, whereas 
elevated levels of dNTP resulted in delay in the S phase entry through unclear 
mechanisms [67, 68], depletion of dNTP pool also resulted in inhibition of DNA 
replication, and fork stalling [69]. In fact, when the enzyme RR was blocked, 
DNA synthesis was arrested, preserving the dNTP for DNA damage repair under 
suboptimal conditions [69, 70].
3.3.2 Mitochondrial dNTP
Mitochondria are one of the major endomembrane organelles in eukaryotic cells 
[14, 71, 72] owing to their ability to produce ATP through oxidative phosphorylation 
as discussed in Section 3.2. Yet they participate in cellular function and dysfunc-
tion, including calcium regulation, activation of cellular death, ROS formation, and 
cellular building block synthesis [73, 74]. In ECs, the mitochondria compromise 
only 6% of cell volume, implicating that EC rely on anaerobic glycolysis rather than 
mitochondria-derived energy [7, 71]. However, mitochondria act primarily as major 
signaling organelles in the ECs and maintain mitochondrial dNTP pools for proper 
EC functions. Additionally, alternation in the levels of mitochondrial ROS has been 
Figure 4. 
Structure of Deoxyribonucleoside Triphosphate (dNTP).
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shown to be associated with impaired one-carbon metabolism, which is essential for 
purines and pyrimidines nucleotides [75, 76].
In response to mild oxidative stress, the mitochondria attempt to re-establish 
homeostasis by ROS-buffering capacity of mitochondria. For example, the 
activity of adenine nucleotide translocase is impaired under mitochondrial 
oxidation, leading to shortage of adenine diphosphate (ADP) [77]. On the other 
hand, up-regulation of mitochondrial anti-oxidant systems and other molecules 
counteract ROS-induced protein unfolding [78, 79]. If oxidative stress is persis-
tent, mitochondria may translate the adaptive response into activation of cellular 
death [74]. These responses and deregulation of ROS levels contribute to the 
pathogenesis of cardiovascular system, including coronary artery diseases.
3.3.3 Fatty acid oxidation (FAO)
Long chain fatty acids are a major source of energy productions, primarily in 
mitochondria [61, 80, 81]. Fatty acids are broken up into acetyl CoA, NADH and 
FADH2 in the mitochondria [80]. These three products are used by the mitochondrial 
matrix for energy production through TCA and oxidative phosphorylation [80].
3.3.3.1 Fatty acid oxidation as a major energy-producing pathway
Fatty acid oxidation (FAO) is an important catabolic and anabolic process. On 
the outer membrane of mitochondria, FAO transfers the acyl group from CoA 
to carnitine by carnitine palmitoyltransferase I (CPT1). Acyl-carnitine is then 
exchanged across the inner membrane of mitochondria. The acyl group is trans-
ferred back again to CoA by carnitine palmitoyltransferase II (CPT II) as shown in 
Figure 5 [82]. CPT1 is an important enzyme for FAO and is a rate limiting factor 
for FAO in the mitochondria. Malonyl CoA, an intermediate product of fatty acid 
synthesis, is an inhibitor of CPT1.
β-oxidation is a four steps process carried by enzymatic oxidation, hydration, 
and oxidation that act on acyl CoA to yield a shorter acyl CoA and acetyl CoA [83]. 
The four-step process is shown in the schematics of Figure 6.
3.3.3.2 Role of fatty acid oxidation in vessel sprouting
Recent studies have shown the critical role of FAO for vessel sprouting [42, 84]. 
In a study, the levels of FAO and dNTP synthesis were reduced when mitochondrial 
CPT1A was silenced. This resulted in impaired vascular sprouting due to reduction 
ECs proliferation but not migration. Additionally, silencing long-chain acyl-CoA 
dehydrogenase (ACADVL) has yielded similar results, supporting the role of FAO 
in vessel sprouting. Overexpression of CPT1A obtained opposite results, further 
supporting a crucial role of CPT1A in angiogenesis.
Substrate ADP GDP CDP UDP
Positive Effector dGTP dTTP ATP ATP
Negative Effector dATP dATP dATP
dGTP
dTTP
dATP
dGTP
dTTP
Table 1. 
Ribonucleotide reductase enzyme regulators.
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3.3.3.3 Fatty acid oxidation for de novo synthesis of nucleotides
As noted above, silencing CPT1A in ECs showed impaired de novo synthesis 
of dNTPs. This impaired de novo dNTP synthesis contributed to reduced vessel 
Figure 5. 
Long-chain fatty acid transportation in the mitochondra. Fatty acids are transported through the mitochondrial 
membrane as acyl CoA for subsequent oxidation. Malonyl CoA acts as a key inhibitor molecule for CPT I, and 
thus regulating the rate of fatty acid oxidation (FAO).
Figure 6. 
Fatty acid β-oxidation pathway.
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sprouting [82]. Nonetheless, the levels of glucose oxidation were increased to com-
pensate for the FAO loss, yet it was not sufficient to help in the proliferative defects 
of ECs with knockdown CPT1A. This reflects the irreplaceable role of FAO for de 
novo dNTP synthesis in ECs [82].
3.3.3.4 Fatty acid β-oxidation in quiescent vs. proliferating endothelial cells
Depending on the cellular status, the FAO are directed either toward DNA syn-
thesis or redox homeostasis. FAO are involved in regenerating NADP+ to NADPH, 
they also upregulate the expression of NADP+ producing genes, which are critical 
for redox homeostasis [43, 82]. Quiescent ECs upregulate FAO, but do not rely on 
them for ATP production or nucleotide synthesis, rather utilize it for redox homeo-
stasis [85]. Unlike quiescent ECs, proliferating ECs utilize FAO for DNA synthesis, 
as previously discussed [82].
CPT1A, the rate limiting enzyme for FAO in mitochondria, has been shown 
to be critical for redox homeostasis in EC. In quiescent ECs, CPT1A inhibition 
caused the levels of ROS to elevate, leading to decreased anti-fibrinolytic gene 
expression, endothelial leakage, and increased leukocytes adhesion and/or 
infiltration [80, 85]. Thus, it is believed that quiescent ECs require more redox 
buffering capacity compared to proliferating ECs due to higher levels of ROS.
Besides the involvement of FAO in redox balance in quiescent ECs, they are also 
involved in other vasculo-protective NADPH-regenerating pathways such as oxida-
tive PPP and nicotine nucleotide transhydrogenase [85].
4. Endothelial metabolism in atherosclerosis
The generation of increased amounts of NO in atherosclerosis is critical for its 
anti-atherogenic effects, including vasodilation, inhibition of platelet aggrega-
tion, smooth muscle proliferation as well as leukocyte migration and oxidative 
stress [38]. Endothelial cells produce NO through enzymatic oxidation of argi-
nine to citrulline via eNOS enzyme. eNOS requires several co-factors including 
NADPH, flavin adenine dineucleotide (FAD), flavin mononeucleotide (FMN), 
Calcium/Calmodulin and tetrahydrobiopterin (BH4). Decreased availability 
of Arginine or deficiency of BH4 results in the paradoxical generation of ROS 
instead of NO by eNOS, a process known as eNOS uncoupling [38, 86]. Arginine 
in particular, has been found to be rate-limiting for NO synthesis in patients with 
atherosclerosis [87]. It was demonstrated that an arginine analog asymmetric 
dimethyl arginine (ADMA), that acts as a competitor for eNOS, impaired NO 
production. ADMA levels are markedly increased in atherosclerosis and therefore 
it is recognized as a major cardiovascular risk factor [88]. Moreover, Dimethyl 
arginine dimethyl aminohydrolase (DDAH), an enzyme that metabolizes ADMA 
into citrulline and dimethylamine is impaired by the oxidative stress in athero-
sclerosis [38]. Interestingly, because of this competition, Arginine supplements 
have been found to be of great benefit in atherosclerotic patients with high 
ADMA levels, by enhancing endothelial-dependent vasodilation and inhibition 
of leukocyte adhesion and migration to the atherosclerotic plaque [89].
Furthermore, endothelial NADPH oxidase is induced by certain athero-
sclerotic plaque components such as the oxidized LDL (oxLDL). The NADPH 
oxidase-derived ROS were found to have detrimental effects in promoting plaque 
progression. These include oxidation of LDLs, inducing vascular smooth muscle 
proliferation and migration and EC apoptosis as well as promoting the expression of 
vascular adhesion adhesion molecules [38].
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5. Conclusions
The endothelium is one of the most diverse tissues in the human body. It main-
tains the integrity of the vascular system and provides nutrition to underlying 
tissues. In addition, EC drives the growth and proliferation of blood vessels under 
physiologic and pathologic conditions. ECs exhibit significant flexibility in response 
to various environmental changes such as hypoxia and ischemia. Careful analysis 
of the process of sprouting angiogenesis explains how ECs function in such an 
orchestrated way to reach their end goal of providing nutrients and oxygen supply 
to the affected tissues. ECs display phenomenal resilience in the process through 
various mechanisms, one of which is their metabolic adaptation and the other is 
critical balance between subcellular levels of ROS (cytosolic versus mitochondrial). 
ECs limit their oxygen consumption in order to preserve it for the tissues that they 
supply to and also to maintain a balanced intracellular redox state. Although ECs 
do not utilize mitochondrial OxPhos for ATP synthesis and thus generate very little 
mitochondrial ROS, NADPH oxidase-derived ROS appear to regulate many critical 
EC functions in health and disease. However, EC has intricated intracellular mecha-
nisms by which subcellular oxidants may communicate at the subcellular levels [7]. 
Unlike most cells in the body (except tumor cells), ECs upregulate and accelerate 
their glycolytic pathways in order to generate energy (ATP production) and certain 
molecules that act as building blocks (dNTPs) and are essential for supporting EC 
proliferation and migration. CPT1A-mediated FAO appears to play a significant role 
in synthesizing dNTPs and NADP+, NADPH in EC mitochondria. Depending on the 
metabolic states of ECs (quiescent versus proliferative), FAO-generated NADPH 
is utilized for quiescent EC’s redox homeostasis or dNTPS for cell proliferation in 
angiogenic endothelium. Further studies aimed at understanding the molecular 
mechanisms by which subcellular ROS modulate EC metabolism in health and 
disease will help develop therapeutics modalities for CVD.
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